Al Roker Insulin and Type 2 Diabetes: How His Journey Compares to Other Public Figures

Al Roker's Type 2 Diabetes History

Al Roker disclosed his type 2 diabetes diagnosis publicly in conjunction with his decision to pursue bariatric surgery. His weight had reached roughly 340 pounds, and he described the diagnosis as a turning point that pushed him toward surgical intervention rather than medication-only management.

The Gastric Bypass Decision

In March 2002, Roker underwent Roux-en-Y gastric bypass at New York's Cornell Medical Center. He discussed the procedure on the Today show, stating that he chose surgery after years of failed dieting and a growing list of metabolic risk factors. The procedure was not cosmetic. It was a clinical decision driven by a hemoglobin A1c that had entered diabetic range and a body mass index well above 40 1.

Post-Surgical Metabolic Outcomes

Roker reported losing more than 100 pounds in the year following surgery. The American Society for Metabolic and Bariatric Surgery notes that Roux-en-Y patients lose 60-80% of excess body weight within 12 to 18 months, with significant improvements in glycemic control occurring as early as days after the procedure 2. Roker's public statements suggest his blood sugar stabilized substantially after surgery, though he has not disclosed specific A1c values. He has described his management as ongoing, involving dietary structure and regular medical follow-up.

Weight Regain and Long-Term Vigilance

Roker has been candid about weight fluctuations over the years. He regained some weight during periods of stress, including after knee replacement surgery in 2019 and a hospitalization for blood clots in late 2022. This pattern is clinically typical. A meta-analysis published in Obesity Surgery found that 20-35% of bariatric patients experience significant weight regain within 2 to 10 years post-procedure 3. Regain does not necessarily mean metabolic relapse, but it does raise the risk of recurrent hyperglycemia.

How Bariatric Surgery Affects Type 2 Diabetes

Bariatric surgery is one of the most effective interventions for T2D remission in patients with obesity. The STAMPEDE trial (Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently) tracked 150 patients with uncontrolled T2D and BMI of 27-43 randomized to intensive medical therapy alone versus medical therapy plus bariatric surgery 4.

The STAMPEDE Trial Results

At 5 years, 29% of Roux-en-Y patients and 23% of sleeve gastrectomy patients achieved the primary endpoint of A1c <6.0% compared to 5% in the medical-therapy-only group. Dr. Philip Schauer, the trial's lead investigator, stated: "Surgery provided durable glycemic control that was superior to intensive medical therapy alone, with meaningful reductions in cardiovascular risk factors" 4.

Hormonal Mechanisms Beyond Weight Loss

The glycemic improvements after bariatric surgery are not explained by weight loss alone. Changes in incretin hormones (particularly GLP-1 and GIP), bile acid signaling, and gut microbiome composition all contribute to improved insulin sensitivity within days of the procedure 5. This explains why many patients see blood sugar normalization before any meaningful weight has been lost.

The ADA's Position

The American Diabetes Association's Standards of Care recommend metabolic surgery as an option for adults with T2D and BMI ≥40, or BMI ≥35 with inadequate glycemic control despite lifestyle and pharmacologic therapy. The 2024 Standards note that "metabolic surgery should be recommended to treat type 2 diabetes in appropriate surgical candidates with BMI ≥40, regardless of the level of glycemic control or complexity of glucose-lowering regimens" 6.

Tom Hanks: Medication-Managed T2D Without Surgery

Tom Hanks revealed his type 2 diabetes diagnosis on Late Show with David Letterman in 2013, describing years of elevated blood sugar that his physician had warned about. Unlike Roker, Hanks has not pursued bariatric surgery.

The Diagnosis Timeline

Hanks stated he had been dealing with high blood sugar since age 36. He was formally diagnosed at 57. His approach has centered on dietary modification and pharmaceutical management. Hanks described a conversation with his doctor: "My doctor said, 'If you can weigh what you weighed in high school, you'll essentially be cured.' I said, 'Well, I'm going to have type 2 diabetes then.'"

Pharmacologic Path

Hanks has not publicly specified which medications he uses, though he has referenced "watching what I eat" and taking prescribed medications. His BMI at the time of diagnosis was estimated in the 25-27 range, placing him in the overweight but not obese category. This is clinically relevant because approximately 10-15% of people with T2D are not obese, a population sometimes called "lean T2D" 7. The pathophysiology in lean T2D may involve greater beta-cell dysfunction relative to insulin resistance, which changes the therapeutic calculus.

Contrast with Roker

The key divergence: Roker's T2D was driven primarily by obesity-related insulin resistance, making bariatric surgery a mechanistically targeted intervention. Hanks's T2D appears more linked to beta-cell decline in the setting of modest overweight, a scenario where surgery is less likely to produce remission. The ADA does not recommend metabolic surgery for patients with BMI <35 outside of clinical trials 6.

Randy Jackson: Gastric Bypass With Ongoing Pharmacotherapy

Former American Idol judge Randy Jackson underwent gastric bypass surgery in 2003, one year after Roker. Jackson was diagnosed with type 2 diabetes at the time and described his blood sugar as "out of control." His starting weight was approximately 350 pounds.

Post-Surgery Course

Jackson lost roughly 100 pounds after surgery, mirroring Roker's trajectory. He has spoken openly about taking metformin for ongoing glycemic management and described himself as "a work in progress." Unlike Roker, Jackson has been more transparent about continued medication use. This pattern is common. Data from the Swedish Obese Subjects (SOS) study showed that even among patients who achieved initial T2D remission after bariatric surgery, approximately 50% had relapsed to diabetic glucose levels at 15 years 8.

Shared Challenges

Both Roker and Jackson have discussed the psychological dimension of weight management after surgery: the surgery changes anatomy but does not eliminate food-related behavioral patterns. Jackson told People magazine that he "still fights cravings every day." The Longitudinal Assessment of Bariatric Surgery (LABS-2) consortium found that 40% of bariatric patients reported problematic eating behaviors at 7 years post-surgery 9.

Drew Carey: Lifestyle-Only T2D Reversal

Drew Carey announced in 2010 that he had lost nearly 80 pounds through diet and exercise alone and that his type 2 diabetes had gone into remission. He did not use bariatric surgery or, by his account, any diabetes medication during the weight-loss phase.

The Approach

Carey adopted a low-carbohydrate diet and began a rigorous exercise routine. He dropped from approximately 262 pounds to 182 pounds. His physician confirmed that his A1c had returned to the non-diabetic range. The DiRECT trial (Diabetes Remission Clinical Trial), published in The Lancet, later provided controlled evidence for this approach: among patients who lost ≥15 kg through dietary intervention, 86% achieved T2D remission at 12 months 10.

Limitations of the Lifestyle-Only Path

Carey's result, while impressive, represents the high end of outcomes. DiRECT found that only 24% of the overall intervention group achieved remission, and the remission rate dropped to 11% at 5 years in a follow-up analysis 11. Sustained weight loss of the magnitude Carey achieved (>30% of excess weight) without surgical or pharmacological support is accomplished by fewer than 5% of patients in long-term observational data 12.

Clinical Takeaway

Carey's success does not invalidate Roker's surgical path. It illustrates that remission is possible through lifestyle alone for some patients, but the probability is much lower, and durability remains uncertain.

Sherri Shepherd: Pre-Diabetes, Intervention, and Relapse Risk

Television host Sherri Shepherd has spoken extensively about her type 2 diabetes diagnosis and her struggle with blood sugar control. She has described periods of medication adherence followed by periods of non-compliance, and she has discussed using insulin at various points.

The Public Health Dimension

Shepherd is an African American woman. Non-Hispanic Black adults are 60% more likely to be diagnosed with T2D than non-Hispanic White adults 13. This disparity is driven by overlapping social, genetic, and environmental factors including food access, healthcare access, and physiological differences in insulin secretion and clearance. Dr. Monica Peek, a professor of medicine at the University of Chicago, has noted: "Racial disparities in diabetes outcomes are not reducible to genetics. They reflect structural determinants of health that compound over a lifetime" 14.

Comparison to Roker

Roker, also African American, shares this elevated baseline risk. His choice of bariatric surgery may reflect, in part, a clinical awareness that T2D in Black patients tends to be diagnosed later, progress faster, and respond less predictably to lifestyle intervention alone 15. Shepherd's more variable course underscores the difficulty of sustained glycemic control through medication and lifestyle modifications without a structural intervention.

The GLP-1 Era: A Pathway These Figures Did Not Have

Roker's surgery predated the widespread availability of GLP-1 receptor agonists for weight management and T2D. Semaglutide (Ozempic for T2D, Wegovy for obesity) received FDA approval in 2017 and 2021, respectively. Tirzepatide (Mounjaro, Zepbound) followed in 2022-2023.

What GLP-1 Agonists Could Have Changed

The STEP 1 trial (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo 16. The SURPASS-4 trial demonstrated that tirzepatide at the 15 mg dose reduced A1c by 2.58 percentage points compared to 1.44 points with insulin glargine in patients with T2D and high cardiovascular risk 17.

Would Roker Have Chosen Differently Today?

This is speculative. A patient presenting in 2025 with Roker's 2002 profile (BMI >45, T2D, failed dietary interventions) would likely be offered GLP-1 agonist therapy as a first-line or adjunctive option before surgery. Some patients respond well enough to avoid the operating room entirely. The SELECT trial (N=17,604) also showed a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients with overweight/obesity and established cardiovascular disease, without requiring diabetes as an entry criterion 18. These cardiovascular benefits add a dimension that was not part of the clinical conversation in 2002.

GLP-1s After Bariatric Surgery

Some clinicians now prescribe GLP-1 agonists to post-bariatric patients who experience weight regain. There is no large randomized trial for this specific population, but retrospective data suggest additional weight loss of 7-12% when GLP-1 agonists are added to post-surgical patients with regain 19. Whether Roker or Jackson have used GLP-1 agonists is not publicly confirmed.

A Framework for Comparing Celebrity T2D Outcomes

Comparing public figures with T2D requires accounting for multiple variables that are rarely disclosed in media interviews.

Variables That Shape Outcomes

BMI at diagnosis determines surgical candidacy and the likely contribution of insulin resistance versus beta-cell failure. Roker and Jackson (BMI >45) fall into a different clinical category than Hanks (BMI ~26).

Duration of disease before intervention matters. Earlier intervention correlates with higher remission rates. The SOS study found that patients who underwent surgery within 2 years of T2D diagnosis had remission rates nearly double those of patients with longer disease duration 8.

Access to care is not equal. All of these individuals are wealthy, with access to top-tier medical teams, nutritionists, and personal trainers. Their outcomes cannot be extrapolated directly to the general population, where cost, insurance coverage, and time constraints limit options. A 2022 analysis in JAMA Network Open found that bariatric surgery utilization was 55% lower among Black patients compared to White patients after adjusting for BMI and comorbidities 20.

Genetics and ethnicity modify T2D progression. Roker, Jackson, and Shepherd share elevated baseline risk as African Americans. Hanks (White, non-Hispanic) may face different pathophysiologic drivers.

What This Means for Patients Considering Their Options

No single celebrity story provides a template. Roker's path through bariatric surgery is supported by strong trial evidence for patients with severe obesity and T2D. Carey's lifestyle-only remission is real but statistically uncommon. Hanks's medication-managed approach is the most typical path for patients with moderate overweight. Jackson's combination of surgery plus ongoing medication reflects the clinical reality for many post-bariatric patients.

The ADA's 2024 Standards of Care emphasize individualized treatment plans that account for BMI, disease duration, comorbidities, patient preference, and available resources 6. Patients with BMI ≥35 and T2D should discuss metabolic surgery with their physician. Patients with BMI <35 may benefit from GLP-1 agonists, SGLT2 inhibitors, or metformin depending on their metabolic profile and cardiovascular risk.

A1c testing every 3 months remains the standard for monitoring glycemic control in active T2D, with a target of <7.0% for most adults and <6.5% for selected patients without significant hypoglycemia risk 6.